Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLUE Monte Rosa Therapeutics

Market Closed 04-24 16:00:00 EDT

19.79

-0.38

-1.88%

盘后19.79

+0.000.00%

17:31 EDT

High20.45	Low19.44	Vol575.50K
Open20.23	D1 Closing20.17	Amplitude5.01%
Mkt Cap1.58B	Tradable Cap1.13B	Total Shares80.02M
T/O11.47M	T/O Rate1.01%	Tradable Shares57.22M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GLUE","market":"US","secType":"STK","nameCN":"Monte Rosa Therapeutics","latestPrice":19.79,"timestamp":1777060800000,"preClose":20.17,"halted":0,"volume":575497,"hourTrading":{"tag":"盘后","latestPrice":19.79,"preClose":19.79,"latestTime":"17:31 EDT","volume":50680,"amount":1002958.03,"timestamp":1777066278456,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01883986117997038,"floatShares":57217800,"shares":80015667,"eps":-0.464974,"marketStatus":"Market Closed","change":-0.38,"latestTime":"04-24 16:00:00 EDT","open":20.23,"high":20.45,"low":19.44,"amount":11470298.615646001,"amplitude":0.050074,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.464974,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777276800000},"marketStatusCode":7,"adr":0,"listingDate":1624507200000,"exchange":"NASDAQ","adjPreClose":20.17,"preHourTrading":{"tag":"盘前","latestPrice":20.35,"preClose":20.17,"latestTime":"08:58 EDT","volume":1253,"amount":25426.781918999997,"timestamp":1777035488320,"change":0.18,"changeRate":0.008924,"amplitude":0.075359},"postHourTrading":{"tag":"盘后","latestPrice":19.79,"preClose":19.79,"latestTime":"17:31 EDT","volume":50680,"amount":1002958.03,"timestamp":1777066278456,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.557222806034172,"impliedVol":0.5901,"impliedVolPercentile":0.0598},"requestUrl":"/m/hq/s/GLUE","defaultTab":"news","newsList":[{"id":"2629800330","title":"What You Need To Know About The Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Analyst Downgrade Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2629800330","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629800330?lang=en_us&edition=fundamental","pubTime":"2026-04-21 18:20","pubTimestamp":1776766838,"startTime":"0","endTime":"0","summary":"One thing we could say about the analysts on Monte Rosa Therapeutics, Inc. ( NASDAQ:GLUE ) - they aren't optimistic...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/what-you-need-to-know-about-the-monte-rosa-therapeutics-inc","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/what-you-need-to-know-about-the-monte-rosa-therapeutics-inc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GLUE",".IXIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628728972","title":"Monte Rosa Therapeutics to present preclinical data on MRT-55811","url":"https://stock-news.laohu8.com/highlight/detail?id=2628728972","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628728972?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:08","pubTimestamp":1776686902,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) announced the company will present preclinical data highlighting the potential of its highly selective, first-in-cla...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-to-present-preclinical-data-on-mrt-55811-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-to-present-preclinical-data-on-mrt-55811-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4230","GLUE","BK4539","BK4139","MRT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628742619","title":"Monte Rosa presents CCNE1 degrader data at AACR meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2628742619","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628742619?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:03","pubTimestamp":1776682984,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics will present preclinical data on cyclin E1 -directed molecular glue degrader MRT-55811 at AACR Annual Meeting 2026 on April 21, 2026.Talk is scheduled for 2:30 p.m. to 4:30 p.m. PT in minisymposium “Targeted Protein Degradation and Non-canonical Oncogenic Signaling.”","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL9M0GyG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4139","IE00BN0W2W23.USD","LU0314104364.USD","BK4588","BK4585","GLUE","LU2210149790.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4112","NDAQ","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2095319765.USD","BK4539","IE00BGHQF748.EUR","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628742604","title":"Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2628742604","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628742604?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:00","pubTimestamp":1776682800,"startTime":"0","endTime":"0","summary":"CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior selectivi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/20/3276859/0/en/Monte-Rosa-Therapeutics-Presents-Preclinical-Data-at-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2026-on-the-Potential-of-its-Cyclin-E1-CCNE1-directed-Molecular-Gl.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4107","AFG","RB","BK4117","BK4539","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627257219","title":"Top Executive’s Surprise Move Shakes Up Monte Rosa Therapeutics Insider Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2627257219","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627257219?lang=en_us&edition=fundamental","pubTime":"2026-04-16 10:03","pubTimestamp":1776305004,"startTime":"0","endTime":"0","summary":"New insider activity at Monte Rosa Therapeutics ( ($GLUE) ) has taken place on April 15, 2026. Monte Rosa Therapeutics has disclosed an insider sto...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executives-surprise-move-shakes-up-monte-rosa-therapeutics-insider-activity-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executives-surprise-move-shakes-up-monte-rosa-therapeutics-insider-activity-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627723710","title":"Monte Rosa CEO Markus Warmuth disposes 8,000 shares for $141,120","url":"https://stock-news.laohu8.com/highlight/detail?id=2627723710","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627723710?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:05","pubTimestamp":1776283543,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics President and CEO Markus Warmuth sold 8,000 shares on April 14, 2026.Sale price was USD 17.64 per share on weighted average basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL3nlh8d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monte Rosa CEO Markus Warmuth disposes 8,000 shares for $141,120","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626144398","title":"Top Monte Rosa Therapeutics Executive Makes Notable Insider Stock Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2626144398","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626144398?lang=en_us&edition=fundamental","pubTime":"2026-04-11 10:03","pubTimestamp":1775873008,"startTime":"0","endTime":"0","summary":"New insider activity at Monte Rosa Therapeutics ( ($GLUE) ) has taken place on April 10, 2026. Monte Rosa Therapeutics’ Chief Business & Legal Offi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-monte-rosa-therapeutics-executive-makes-notable-insider-stock-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-monte-rosa-therapeutics-executive-makes-notable-insider-stock-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626110216","title":"Monte Rosa Chief Business & Legal Officer Philip Nickson sells 5,845 shares for $103,410","url":"https://stock-news.laohu8.com/highlight/detail?id=2626110216","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626110216?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:09","pubTimestamp":1775851778,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Chief Business & Legal Officer Philip Nickson sold 5,845 shares on April 9, 2026.Sale priced at weighted average USD 17.69 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL3XNc85:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monte Rosa Chief Business & Legal Officer Philip Nickson sells 5,845 shares for $103,410","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623393763","title":"Monte Rosa Therapeutics Inc : Jefferies Assumes Coverage With Buy Rating; Target Price $30 VS $31","url":"https://stock-news.laohu8.com/highlight/detail?id=2623393763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623393763?lang=en_us&edition=fundamental","pubTime":"2026-03-30 13:04","pubTimestamp":1774847066,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40I03P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622738257","title":"A Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2622738257","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622738257?lang=en_us&edition=fundamental","pubTime":"2026-03-28 23:07","pubTimestamp":1774710427,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) has moved into focus after signing a supply agreement with Johnson & Johnson to evaluate MRT-2359 plus ERLEADA in a planned Phase 2 trial for metastatic castration-resistant prostate cancer.\nSee our latest analysis for Monte Rosa Therapeutics.\nAlongside the Johnson & Johnson supply agreement and fresh MRT-2359 data, Monte Rosa’s share price has eased recently. The stock has a 30 day share price return of 15% and a 90 day share price return decline of 11%. At the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/a-look-at-monte-rosa-therapeutics-glue-valuation-after-johns","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/a-look-at-monte-rosa-therapeutics-glue-valuation-after-johns","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1430594728.SGD","IE00B19Z3B42.SGD","IE0002141913.USD","LU0203347892.USD","JNJ","IE00BVYPNW00.USD","BK4504","LU2750360641.GBP","LU2468319806.SGD","LU0795875169.SGD","GLUE","IE00B7SZLL34.SGD","IE0002270589.USD","IE00BN8TJ469.HKD","BK4532","MRT","LU2347655156.SGD","LU1732800096.USD","LU1894683264.USD","LU2471134523.USD","LU1023059063.AUD","LU1894683348.USD","IE00B1BXHZ80.USD","LU0124676726.USD","IE00BFTCPJ56.SGD","LU2112291526.USD","LU0289739699.SGD","BK4581","LU1983299246.USD","LU1066051811.HKD","LU1162221912.USD","LU1244550221.USD","LU1718418525.SGD","IE00B42XCP33.USD","BK4588","IE00BFXG1179.USD","BK4139","BK4533","IE00BJJMRZ35.SGD","LU2750360997.AUD","LU2133065610.SGD","IE00BLSP4452.SGD","LU0795875086.SGD","LU1074936037.SGD","LU1032466523.USD","IE00BSNM7G36.USD","LU2430703178.SGD","LU2471134952.CNY","DCF","LU1674673691.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621793962","title":"A Look At Monte Rosa Therapeutics (GLUE) Valuation After Its Recent Share Price Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2621793962","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621793962?lang=en_us&edition=fundamental","pubTime":"2026-03-21 22:05","pubTimestamp":1774101915,"startTime":"0","endTime":"0","summary":"Event overview and recent performance\nMonte Rosa Therapeutics (GLUE) has drawn fresh attention after recent trading. The stock closed at US$15.63 and recorded a 14.5% decline over the past month, alongside a small gain over the past 3 months.\nSee our latest analysis for Monte Rosa Therapeutics.\nFor context, the recent 14.5% one-month share price decline comes after a far stronger longer run. The 1-year total shareholder return is 169.5% and the 3-year total shareholder return is 131.9%. This...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/a-look-at-monte-rosa-therapeutics-glue-valuation-after-its-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/a-look-at-monte-rosa-therapeutics-glue-valuation-after-its-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","DCF","BK4139","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620247415","title":"J.P. Morgan Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247415","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247415?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:59","pubTimestamp":1773921578,"startTime":"0","endTime":"0","summary":"In a report released today, Brian Cheng from J.P. Morgan maintained a Buy rating on Monte Rosa Therapeutics, with a price target of $30.00. Accordi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-keeps-their-buy-rating-on-monte-rosa-therapeutics-glue-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-keeps-their-buy-rating-on-monte-rosa-therapeutics-glue-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620829251","title":"Monte Rosa Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2620829251","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620829251?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:31","pubTimestamp":1773840691,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryMonte Rosa Therapeutics Inc GLUE.OQ reported a quarterly adjusted loss of 56 cents per share for the qua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL8N4061HC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620825623","title":"Monte Rosa Therapeutics Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2620825623","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620825623?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:01","pubTimestamp":1773838860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GLUE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 09:01 ET (13:01 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620375072","title":"Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620375072","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620375072?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:45","pubTimestamp":1773830758,"startTime":"0","endTime":"0","summary":"In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Monte Rosa Therapeutics, with a price target of $29.00. Accor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-monte-rosa-therapeutics-glue-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-monte-rosa-therapeutics-glue-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620420382","title":"Sector Update: Health Care Stocks Mixed Premarket Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420382","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620420382?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:16","pubTimestamp":1773753404,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF  down 0.1% and the iShares Biotechnology ETF  0.4% higher.Eupraxia Pharmaceuticals  shares were up more than 1% after the company said data from its ongoing trial evaluating EP-104GI for eosinophilic esophagitis treatment showed 59% of patients achieved clinical remission at 12 weeks.Monte Rosa Therapeutics  stock was down 1% after the company reported that it swung to a Q4 net loss as collaboration revenue declined during the period.Lensar  shares were down more than 24% after the company said it has reached an agreement with Alcon  to terminate their planned merger.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPRX","BK4581","LU1804176565.USD","BK4198","BK4534","BK4588","LABU","XLV","GLUE","ALC","BK4585","LU2265009873.SGD","BK4082","BK4539","LNSR","IBB","BK4139","XBI","BK7094","ALC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620429675","title":"Monte Rosa Therapeutics Inc. publishes corporate presentation on molecular glue degrader pipeline with three clinical programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429675","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429675?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:25","pubTimestamp":1773746732,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Inc. publishes corporate presentation on molecular glue degrader pipeline with three clinical programs. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL7M6J4J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLUE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620175426","title":"Monte Rosa Q4 net loss widens 244% to USD 46.14 million on revenue down 95% to USD 2.78 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620175426","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620175426?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:03","pubTimestamp":1773745431,"startTime":"0","endTime":"0","summary":"Monte Rosa published a press release reporting Q4 and full-year 2025 financial results and business updates. Q4 collaboration revenue fell 95.41% to USD 2.78 million, and R&D expenses rose 7.99% to USD 41.98 million, driven by increased spending on MRT-8102 and other development and discovery programs. Q4 net loss was USD 46.14 million, and cash, cash equivalents, restricted cash and marketable securities totaled USD 382.1 million as of Dec. 31, 2025. For FY 2025, collaboration revenue rose 63.54% to USD 123.67 million, while R&D expenses increased 16.36% to USD 141.5 million. FY 2025 net loss was USD 38.63 million, and Markus Warmuth said the company’s cash runway extends into 2029 following an upsized follow-on financing with gross proceeds of about USD 345 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL2djWYD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","IE00BKPKM429.USD","SG9999014039.USD","BK4139","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD","IE00BN0W2T93.GBP","BK4588","BK4539","IE00B3QW5Z07.USD","SG9999014013.SGD","NDAQ","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","LU2095319765.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620269464","title":"BRIEF-Monte Rosa Therapeutics Q4 Operating Income USD -49.715 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620269464","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620269464?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:00","pubTimestamp":1773745246,"startTime":"0","endTime":"0","summary":"BRIEF-Monte Rosa Therapeutics Q4 Operating Income USD -49.715 Million\n\n\nMar 17 (Reuters) - Monte Rosa Therapeutics Q4 operating expenses USD 52.496 million.\n\nQ4 collaboration revenue USD 2.781 million\nQ4 net income USD -46.135 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nPLX74DB4C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLUE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620942659","title":"Monte Rosa Therapeutics Q4 Net Income USD -46.135 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620942659?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:00","pubTimestamp":1773745201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nPLX74DB4C:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","GLUE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monterosatx.com","stockEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.2597},{"period":"3month","weight":-0.1335},{"period":"6month","weight":0.7765},{"period":"1year","weight":2.7912},{"period":"ytd","weight":0.2621}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.040424},{"month":2,"riseRate":0.4,"avgChangeRate":-0.031875},{"month":3,"riseRate":0.4,"avgChangeRate":0.028615},{"month":4,"riseRate":0.4,"avgChangeRate":-0.12478},{"month":5,"riseRate":0.25,"avgChangeRate":-0.009649},{"month":6,"riseRate":0.5,"avgChangeRate":0.041063},{"month":7,"riseRate":0.8,"avgChangeRate":0.071272},{"month":8,"riseRate":0.4,"avgChangeRate":0.098753},{"month":9,"riseRate":0.4,"avgChangeRate":-0.025082},{"month":10,"riseRate":0.8,"avgChangeRate":0.245263},{"month":11,"riseRate":0.4,"avgChangeRate":0.027512},{"month":12,"riseRate":0.4,"avgChangeRate":0.082538}],"exchange":"NASDAQ","name":"Monte Rosa Therapeutics","nameEN":"Monte Rosa Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monte Rosa Therapeutics,GLUE,Monte Rosa Therapeutics股票,Monte Rosa Therapeutics股票老虎,Monte Rosa Therapeutics股票老虎国际,Monte Rosa Therapeutics行情,Monte Rosa Therapeutics股票行情,Monte Rosa Therapeutics股价,Monte Rosa Therapeutics股市,Monte Rosa Therapeutics股票价格,Monte Rosa Therapeutics股票交易,Monte Rosa Therapeutics股票购买,Monte Rosa Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction